



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
CORPORATION FINANCE

Mail Stop 4645

February 14, 2017

Jeffrey A. Munsie
General Counsel
Merrimack Pharmaceuticals, Inc.
One Kendall Square, Suite B7201
Cambridge, Massachusetts 02139

**Re: Merrimack Pharmaceuticals, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed January 24, 2017
File No. 001-35409**

Dear Mr. Munsie:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

/s/ Joseph McCann for

Suzanne Hayes
Assistant Director
Office of Healthcare and Insurance

Cc: Katherine D. Ashley
Graham Robinson
Skadden, Arps, Slate, Meagher & Flom LLP